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Abstract
Purpose Human interleukin-21 (IL-21) is a class I cyto-
kine previously reported in clinical studies on immune
responsive cancers. Here we report the eVects of systemic
IL-21 therapy on the immune system in two phase 1 trials
with this novel cytokine.
Experimental design Recombinant IL-21 was adminis-
tered by intravenous bolus injection at dose levels from 1 to
100 g/kg using two planned treatment regimens: thrice
weekly for 6 weeks (3/week); or once daily for Wve consec-
utive days followed by nine dose-free days (5 + 9). The
following biomarkers were studied in peripheral blood
mononuclear cells (PBMC) during treatment: phosphorylation
of STAT3, alterations in the composition of leukocyte
subsets, ex vivo cytotoxicity, expression of eVector molecules
in enriched CD8+ T cells and CD56+ NK cells by quantitative
RT-PCR, and gene array proWling of CD8+ T cells.
Results EVects of IL-21 were observed at all dose levels.
In the 5 + 9 regimen IL-21 induced a dose dependent
decrease in circulating NK cells and T cells followed by a
return to baseline in resting periods. In both CD8+ T cells
and CD56+ NK cells we found up-regulation of perforin
and granzyme B mRNA. In addition, full transcriptome
analysis of CD8+ T cells displayed changes in several tran-
scripts associated with increased cell cycle progression, cel-
lular motility, and immune activation. Finally, cytotoxicity
assays showed that IL-21 enhanced the ability of NK cells
to kill sensitive targets ex vivo.
Conclusions IL-21 was biologically active at all dose
levels administered with evidence of in vivo NK cell and
CD8+ T cell activation.
Keywords Immune activation · IL-21 · Cytokines · 
Immunotherapy
Introduction
IL-21 is a cytokine belonging to the common -chain fam-
ily of cytokines, which also includes IL-2, IL-4, IL-7, IL-9
and IL-15. IL-21 is produced by activated CD4+ T cells and
NKT cells and is induced by IL-6 and by a positive auto-
crine feedback loop [8, 35]. Follicular helper T cells have
been shown to be a major source of IL-21 [7]. Similar to the
other common -chain family of cytokines IL-21 signals
through the Janus activated kinase (Jak)/signal transducer
and activator of transcription (STAT) pathway, with
STAT1 and STAT3 as major targets. In addition signaling
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through STAT4, STAT6, MAPK and PI3K pathways have
been demonstrated [11,  51]. IL-21 promotes activation,
cytokine and antigen-dependent proliferation of CD8+ T
cells as well as NK cell activation and cytolytic activity [4,
26, 35, 50]. In contrast to IL-2, IL-21 does not promote the
proliferation and activity of Treg cells [36] but inhibits the
generation of human Treg cells in vitro [25]. Together with
IL-6, IL-21 is a main driver of Th17 cell diVerentiation [22,
23, 34, 52], but depending on the context IL-21 can also
promote both Th1 and Th2 responses [42], suggesting that
IL-21 may play a role in autoimmune diseases [13, 48]. IL-
21 has both proliferative and pro-apoptotic eVects on B
cells and promotes isotype switching and diVerentiation of
B cells into plasma cells leading to increased immunoglob-
ulin production (reviewed in [24]). In animal models IL-21
enhances anti-tumor immunity through mechanisms that
require NK cells and/or CD8+ T cells depending on the model
used [4, 27, 30, 40], and IL-21 therapy can lead to sustained
tumor-speciWc CD8+ T cell responses [30], suggesting that
IL-21 may be useful as an immunotherapeutic to treat cancer.
Metastatic melanoma (MM) and stage IV renal cell car-
cinoma (RCC) are two diseases commonly used for testing
experimental immunotherapies due to a well described his-
tory of responsiveness to immune modulation in these indi-
cations [17, 37]. The Wve-year survival for MM is 5–10%
with a median survival of the order of seven months [2, 3].
Recombinant human IL-21 (IL-21) is being developed for
clinical use by both ZymoGenetics Inc. and Novo Nordisk
A/S. Two phase 1 dose escalation trials of recombinant
human IL-21 administered intravenously to MM or RCC
patients have recently been conducted showing a favorable
safety proWle and signs of clinical activity [9, 45]. Due
to these positive results, IL-21 is now in phase 2 trials
for MM, RCC, and non-Hodgkin’s lymphoma (clinical-
trials.gov identiWers NCT 00336986, NCT00389285,
NCT00347971). Here we have investigated the systemic
immune eVects of IL-21 in blood samples taken from
patients in these two phase 1 trials. We have measured
alterations in lymphocyte subsets and CD8+ T cell activa-
tion markers by Xow cytometry, performed transcriptional
proWling on enriched CD8+ T cells and carried out ex vivo
cytotoxicity assays. Our results conWrm that IL-21 at the
administered doses was immunologically active in patients
with advanced MM and RCC.
Materials and methods
Trial design and patient population
Seventy-two patients were evaluated in two phase 1 dose
escalation studies conducted in Australia and the United
States. The Australian study was conducted in patients with
MM [9], while the US study was conducted in patients with
either MM or RCC [45]. Both trials were open-label dose
escalation phase 1 studies of recombinant human IL-21
administered by intravenous bolus injection. The primary
objective was to assess the safety and tolerability of IL-21
at various dose levels and dosing regimens by determining
dose-limiting toxicity (DLT) and estimating a maximum
tolerated dose (MTD). Secondary objectives were to: iden-
tify a dose response for various biomarkers in the periphe-
ral blood; estimate the minimum biologically eVective dose
(BED); determine the pharmacokinetics of IL-21; deter-
mine if anti-IL-21 antibodies were induced during therapy;
and measure eVects on tumor size.
In the Australian study the patients were allocated non-
randomly in cohorts of two patients into one of two parallel
treatment arms: treatment thrice weekly (Monday, Wednes-
day, Friday) for six weeks (3/week); or three cycles of daily
dosing for Wve days followed by nine days of rest (5 + 9). If
there was no symptomatic tumor progression at the week 8
assessment that required treatment by another modality,
further treatment with use of the same dose and regimen
was oVered. In the US study patients were planned to
receive two cycles of the 5 + 9 regimen, although for some
patients the recovery period of 9 days was prolonged to
16 days to allow recovery from IL-21-induced toxicity. Eli-
gible patients had histologically conWrmed surgically incur-
able metastatic malignant melanoma. The US trial also
included patients with metastatic RCC of predominantly
clear cell histology. Details on inclusion criteria and disease
assessment have been published previously [9]. The MTD
was estimated to be 30 g/kg for both treatment schedules.
In the US trial another 30 patients were treated at the MTD
to provide further data on safety and eYcacy.
All patients provided written informed consent prior to
any study-speciWc procedures. The Australian trial proto-
col was approved by the Human Research Ethics Commit-
tees of the participating institutions and was performed
under the Australian Therapeutic Goods Administration
Clinical Trials NotiWcation (CTN) scheme. The study
sponsor was Novo Nordisk A/S. In the US trial the institu-
tional review boards of participating medical centers approved
the protocol and associated materials, and patients gave writ-
ten informed consent before study-speciWc procedures began.
Manufacturing of IL-21
The process for production, refolding and puriWcation of
the IL-21 molecule as well as analytical methods for assess-
ing purity and potency were developed by ZymoGenetics
Inc. Recombinant human IL-21 is expressed in E. coli
as the N-terminal methionylated form of the molecule.
Manufacturing of the product was carried out in the GMP
facilities of Avecia, Ltd., UK.Cancer Immunol Immunother (2008) 57:1439–1449 1441
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STAT3 phosphorylation assay
This assay was carried out only in the Australian trial. Blood
samples (2 mL) were drawn into lithium heparinized tubes
immediately prior to the Wrst IL-21 dosing (pre-sample) and
15 min after IL-21 dosing (post-sample). The pre-sample
was split into two tubes. One tube was immediately put on
ice and stored at <4°C until further processing to serve as
negative/unstimulated control. To the second tube IL-21 was
added to a concentration of 10 ng/mL, where after the tube
was incubated for 15 min at RT to serve as the positive,
patient-speciWc control. This dose of IL-21 is suYcient to
induce maximal STAT3 phosphorylation, although the fact
that stimulation was carried out at RT may have resulted in
slightly lower STAT3 phosphorylation than would have
been observed at 37°C (data not shown). After drawing the
post treatment-sample all three samples were Wxed by trans-
ferring 500 L from each sample to tubes containing 9 mL
FACS Lysing solution (BD Biosciences, San Jose, CA) and
stored up to 120 min on ice. During this step samples were
transferred to the laboratory at Cancer Trials Australia
(Parkville, Victoria, Australia) where the remaining proce-
dure was carried out. The cells were subsequently washed in
PBS containing 1% FCS and Wxed by incubation in 2%
paraformaldehyde for 10 min at 37°C. Cells were washed
again and resuspended in 90% methanol to permeabilize
cells. At this step cells were frozen and kept at ¡80°C until
further analysis. Cells were washed and stained for 1 h at RT
with PE labeled antibody directed against STAT3 (pY705),
clone 4, and FITC labeled CD3 antibody, clone UCHT1
(BD Biosciences). Cells were washed again and acquisition
was done on a FACSCalibur (BD Biosciences). Data were
analyzed using FACSDiva software (BD Biosciences).
Flow cytometry
US trial: Whole blood was collected into 3 mL heparin
tubes for FACS analysis from each subject enrolled in the
study. Samples were collected prior to dosing on Days 1
and 4 and on Day 10 of both dosing cycles. All samples
were shipped overnight at ambient temperature to Esoterix
Laboratory Services (East Windsor, NJ), and analyzed
within 24 h of receipt. For each sample, 100 L of whole
blood was placed in TruCount tubes (BD Biosciences), and
incubated with the appropriate dilutions of antibodies. The
following antibodies were used for immunophenotyping:
CD4 (clone SK3), CD8 (clone SK1), CD56 (clone
NCAM16.2), CD45 (clone 2D1), CD14 (clone MP9),
CD25 (clone 2A3), and CD38 (clone HB7) were from BD
Biosciences; CD3 (clone UCHT1) was from Immunotech;
CD19 (clone HIB19) was from BD Pharmingen. Red blood
cells were lysed using FACS Lysing Solution (BD Biosci-
ences). After processing, Ab-stained samples were ana-
lyzed on a FACS Calibur Xow cytometer using CellQuest
acquisition software (version 3.3, BD Biosciences).
Acquired data were analyzed with WinList Xow cytometry
data analysis software (version 3.0, Verity Software House,
Topsham, ME). Responses to IL-21 dosing were assessed
by factorial analysis of variance with repeated measures
using JMP v5.1 (SAS Institute, Cary, NC).
Australian trial: Prior to IL-21 dosing, 5–10 mL blood
were drawn into Lithium Heparin tubes (BD Biosciences)
at Day 1 and Day 5. Blood samples were transferred at
ambient temperature to Department of Haematology, Royal
Melbourne Hospital, Australia and PBMC were prepared
by density gradient centrifugation using Multi-Q-prep
method (Beckman Coulter, Fullerton, CA) and resuspended
in PBS with BSA to a Wnal volume of 3.6 mL. The follow-
ing list of antibodies was employed for labelling of blood
cells prior to Xow cytometric analysis; CD3 (clone
UCHT1), CD4 (clone SK3), CD8 (clone T8), CD45 (clone
J.33) were from Beckman Coulter and CD45RA (clone
L48), CCR7 (clone 3D12) and CD62L (clone DREG-56)
were from BD Biosciences. Cells were incubated at room
temperature for 10 min with the antibodies prior to Xow
cytometry. After labelling, red blood cells were lysed and
Wxed. Acquisition was done on a XL-MCL instrument
(Beckman Coulter) and data analysis performed with
Expo32 software (Beckman Coulter).
Quantitative real-time RT-PCR (qRT-PCR) and microarray 
analysis
In the Australian trial citrated blood samples were collected
from patients on Day 1 (before Wrst IL-21 dose) and on Day
5. CD8+ cells were enriched as previously described [9]; in
addition CD56 positive cells were enriched using CD56
Microbeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) and a magnetic MiniMACS Separation Unit (Milte-
nyi Biotec). Enriched cells were lysed in RNA extraction
buVer and total RNA isolated as previously described. Fifty
nanograms of total RNA was used to prepare targets by
Two-Cycle Target labeling kit (AVymetrix, Santa Clara,
Ca, USA) following the instructions of the manufacturer.
Hybridization cocktails were hybridised onto Human
Genome U133 Plus 2.0 GeneChips® (AVymetrix) at 45°C
for 17 h (60 RPM) in a Hybridization Oven 640 (AVyme-
trix). GeneChips® were washed and stained in a GeneChip®
Xuidics station 450 using the Xuidics protocol “EukGE-
WS2v5_450” (AVymetrix). Chips were scanned in a Gene-
Chip® scanner 3000 (AVymetrix).
For qRT-PCR analyses, cDNA was either prepared from
total RNA (granzyme B and perforin-1 analyses) or from
each of the IVT cRNA preparations (granzyme A,
interferon-, CXCR3, and hyaluronan-mediated motility
receptor (HMMR) analyses (conWrming array results))1442 Cancer Immunol Immunother (2008) 57:1439–1449
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using random primers and TaqMan Reverse Transcription
reagents (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions. Quantitative
PCR was performed in duplicate on each of the cDNA sam-
ples (tenfold dilutions of cDNA) using TaqMan PCR core
reagents (Applied Biosystems) and the ABI PRISM®
7900HT Sequence Detection System (Applied Biosys-
tems). Primers and FAM-labeled-probes for granzyme B
mRNA, granzyme A mRNA, perforin-1 mRNA, interferon-
 mRNA, CXCR3 mRNA, HMMR mRNA, TATA-binding
protein mRNA, and 18S rRNA, were ordered as Assays-on-
Demand (Applied Biosystems). Probe sequences for these
assays were as follows: CXCR3 (ATGGTCCTTGAGGTG
AGTGACCACC (assay Hs00171041_m1)), granzyme B
(CTTCCTTTAAGGGGGACTCTGGAGG (assay Hs00
188051_m1)), granzyme A (TCCTGCTAATTCCTGAAG
ATGTCTG (assay Hs00196206_m1)), perforin-1 (GAGTG
CCGCTTCTACAGTTTCCATG (assay Hs00169473_ m1)),
interferon- (AGAAATATTTTAATGCAGGTCATTC
(assay Hs00174143_m1)), HMMR (GCTGAAAGG
GAAGGAGGCTGAACTG (assay Hs00234864_m1)),
TATA binding protein (TGGGTTTTCCAGCTAAGTTCT
TGGA (assay Hs99999910_s1)), and 18S rRNA (TGGAG
GGCAAGTCTGGTGCCAGCAG; assay Hs99999901_s1).
Data were analyzed using ABI Prism SDS 2.2 software
(Applied Biosystems), and expression levels for granzyme
A, interferon-, CXCR3, and HMMR were normalized to
TATA binding protein levels whereas perforin-1 and gran-
zyme B were normalized to 18S rRNA levels.
Cytotoxicity assay
In the Australian trial heparinized blood was collected into
CPT tubes (BD Biosciences) from the patients at screening
(typically 1–2 weeks before Wrst IL-21 dose) and at study
day 1, and day 5 prior to dosing. PBMC were subsequently
prepared by centrifugation, frozen in FCS with 10%
DMSO and stored for up to one year in liquid nitrogen.
Using PBMC from normal donors we have observed that
this procedure may decrease cytotoxicity up to 50%. To
perform the cytotoxicity assay cells were thawed and
tested as eVector cells in a standard 4 h 51Cr-release assay
using  51Cr-labeled K562 erytholeukemia cells as target
cells. For each patient all samples were run together in one
assay in order to avoid inter-assay variation. When suY-
cient cells were available the fraction of NK cells was
measured by Xow cytometry as described above after
thawing of the cells.
Statistical analysis
Microarray data were normalized and gene expression mea-
sures derived using the RMA algorithm, and S-PLUS ver-
sion 7.0 and SAS version 9.1 were used for the statistical
analysis. The logged gene expression levels from day 1 and
day 5 samples from the 25 patients were Wtted to a log dose
ANCOVA model assuming that the regulation of a probeset
is proportional to the log of the dose. A false discovery rate
(FDR) of 1% was used (meaning that the expected percent
of false positives is 1%). Clustering and heat-map genera-
tion of gene expression data were done using R (http://
www.R-project.org). Log fold ratios (day 5 samples com-
pared to day 1 samples (paired samples from individual
patients)) were clustered hierarchically by complete linkage
and euclidian distance. The Heatplus and geneplotter pack-
ages were used for generation of the clustered heatmap
whereas GO, GOstats, and Rgraphviz packages were
used for GO analysis and construction of the GO-tree
(http://www.bioconductor.org). DiVerentially regulated
probesets were also analysed using Ingenuity Pathway
Analyses (http://www.ingenuity.com). Immune related
genes (Fig. 3b) were identiWed by Wltering genes containing
the GO-term “immune regulation” or “immunological
synapse”.
Results
Analysis of STAT3 phosphorylation
Upon engagement of IL-21R the primary signal transduc-
tion events are the activation of Janus kinase (Jak)1 and
Jak3 leading to phosphorylation of STAT1 and STAT3 [1,
41]. As a primary marker of biological activity STAT3
phosphorylation was measured in 29 patients from the Aus-
tralian trial. Based on in vitro studies we found that the
optimal time for measuring STAT3 phosphorylation was
15 min after IL-21 administration as phosphorylated
STAT3 (pSTAT3) is subsequently lost (data not shown),
probably due to the action of the negative modulator,
SOCS1, which has been shown to be induced by IL-21
[14]. We measured pSTAT3 by Xow cytometry in whole
blood samples drawn immediately before and 15 min after
IL-21 dosing. We found that even at the lowest dose level
(1 g/kg) there was maximal induction of pSTAT3 in CD3+
T cells slightly higher than the in vitro positive control
(Fig. 1a). In addition pSTAT3 was induced in a fraction of
CD3¡ lymphocytes. Although we did not include markers
for B cells and NK cells in these stainings, the non-T cells
responding to IL-21 is likely to be a mix of both B cells and
NK cells, since in vitro studies using blood from normal
donors have shown that pSTAT3 is induced in a fraction of
both B cells and NK cells upon IL-21 stimulation (data not
shown). IL-21 induced similar levels of STAT3 phosphory-
lation at all dose levels (Fig. 1b) showing that IL-21 was
biologically active even at the lowest dose.Cancer Immunol Immunother (2008) 57:1439–1449 1443
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EVect on lymphocyte subsets
In the US trial blood samples were drawn on day 1, 4 and
10 during the Wrst and second cycle of IL-21 treatment and
three weeks following the Wnal IL-21 dose. These were ana-
lyzed by Xow cytometry for changes in the number of lym-
phocyte subsets. The absolute number of lymphocytes
decreased in a dose-dependent fashion by trial day 4 but
returned to pre-dose levels or slightly higher on day 10
(Fig. 2a). No change was observed from Wrst to second dos-
ing cycle (Fig. 2b). The number of CD4+ and CD8+ T cells,
B cells and NK cells all decreased during dosing with the
NK cells showing the most profound decrease, whereas
monocytes increased (Fig. 2c). On day 10, 5 days after ces-
sation of dosing, monocytes, T cells and NK cells returned
to baseline whereas B cell numbers increased slightly
beyond baseline levels. Similar results have been obtained
from the Australian trial (data not shown). No change in the
fraction of activated (CD25+) T cells was seen during dos-
ing (data not shown) but the percent activated T cells
increased from 14.9 § 2.3 pre-dose to 21.4 § 1.7 three
weeks following the Wnal IL-21 dose. Within the B cell
population the fraction of naïve B cells, deWned as
CD19+CD38¡ decreased during dosing and the fraction of
plasma B cells, deWned as CD19+CD38HI increased during
dosing (Fig. 2d). The plasma cells returned to baseline upon
cessation of treatment, whereas the percent naïve B cells
remained repressed three weeks following the Wnal IL-21
Fig. 1 IL-21 induced STAT3 phosphorylation at all dose levels.
Whole blood was drawn immediately before the Wrst IL-21 dose and
15 min after dosing. Half of the pre-dose sample was stimulated for
15 min ex vivo with 10 ng/mL IL-21 to provide a positive control.
Samples were analyzed by Xow cytometry for pSTAT3 in CD3+ T
cells. a Representative dot plots of pre-dosing, post-dosing and ex vivo
positive control samples. b For each dose level the average pSTAT3
mean Xuorescence intensity in CD3+ T cells in percent of the ex vivo
positive control samples is shown
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dose (14.3 § 1.8% post-dosing compared to 17.9 § 2.1%
pre-dose).
In the Australian trial responses during IL-21 treatment
were assessed in peripheral blood mononuclear cells
(PBMC) by Xow cytometric analysis of cell surface mark-
ers on CD8+ T cells. Upon IL-21 treatment, the most pre-
dominant changes were an increase at day 5 in the
frequency of CD62L and CCR7 positive CD8+ T cells. This
increase was seen in a total of 14 out of 14 and 8 out of 10
evaluable subjects in the 5 + 9 regimen for CCR7 and
CD62L, respectively (Fig. 2e, f). Moreover, we found an
increase in the frequency of naïve (CD45RA+) CD8+ T
cells in a total of 11 out of 14 subjects in the 5 + 9 regimen
(Fig. 2g). No dose response relationship was observed for
any of these parameters. Changes were less prominent in
the 3/week regimen (data not shown), which may be due to
the fact that patients in this regimen had received only two
doses of IL-21 on day 5 compared to four doses in the 5 + 9
regimen, and sampling was done 48 h after the day 3 dose
in the 3/week regimen compared to 24 h after the last dose
in 5 + 9 regimen. Thus, results are not directly comparable
between the regimens.
Full transcriptome analysis on CD8+ cells:
Microarray data from 25 patients from the Australian study
were used for identifying IL-21-mediated transcriptional
regulations in CD8+ cells. CD8+ cells were isolated from
peripheral blood on day 1 prior to the Wrst IL-21 dose and
on day 5 prior to dosing and analysed for transcriptional
changes. With a FDR of 1%, 6116 probe sets were found to
be diVerentially regulated when the data were Wtted to a log
dose model. The log dose model assumes that the regula-
tion of a gene is proportional to the log of the dose. Adding
the criteria that average gene regulations at least should be
twofold in either dose level 4, 5, or 6 (level 4 = 30 g/kg;
level 5 = 50 g/kg; level 6 = 100 g/kg), 471 probe sets
were identiWed (Electronic supplementary Table 1).
To obtain an overview of the functional roles of the reg-
ulated genes, the 471 probe sets were analyzed for statisti-
cal overrepresented gene ontology (GO-) terms, describing
genes overrepresented in diVerent functional categories. A
very clear overrepresentation was found for genes involved
in cell cycle (Fig. 3a and ESM Table 2). The six most sig-
niWcant GO-terms are all directly cell cycle related (1:“cell
cycle”, 2:“mitotic cell cycle”, 3:“cell division”, 4:“M
phase”, 5:“mitosis”, and 6:“M phase of mitotic cell cycle”).
The next four GO-terms are also clearly relatable to cell
division; 7:“DNA replication”, 8:“DNA metabolism”,
9:“spindle organization and biogenesis”, and 10:“microtu-
bule-based process”. This GO-term analysis clearly sug-
gests an increased proliferation of the CD8+ cells on day 5
compared to day 1. On the gene level this is exempliWed by
the clear upregulations of cyclin A2, cyclin B1, cyclin B2,
cyclin E1, and cyclin E2 with average fold-regulations from
»4 to »13 (when averaging patients from level 4, 5, and 6
(ESM Table 1)). The cyclin up-regulations are part of a reg-
ulatory cascade that controls the activity of cyclin-depen-
dent kinase 2 (CDK2), and phosphorylation of downstream
targets involved in the initiation of DNA replication (S-
phase)[32]. CDK2 and the proliferation markers PCNA
(proliferating cell nuclear antigen) and Ki67 antigen (anti-
gen identiWed by monoclonal antibody Ki-67) were also
found to be signiWcantly up-regulated (ESM Table 1). The
functional roles of the diVerentially expressed genes were
also analyzed using ingenuity pathway analysis (IPA). In
agreement with the GO-term analysis, the top three func-
tions found in IPA were “Cell Cycle”, “DNA Replication,
Recombination, and Repair”, and “Cellular Assembly and
Organization (e.g, “segregation of chromosomes”, and
“formation of mitotic spindle”) (data not shown).
Quantitative RT-PCR analysis
Although genes involved in immune functions were not
among the highest represented GO-terms a separate analysis
showed that several genes involved in immune function were
regulated by IL-21 (Fig. 3b). Two of the highest up-regulated
genes in this list were interferon (IFN)- and granzyme B (see
appendix a), both of which are classical markers of eVector
T-cells. Quantitative RT-PCR analysis was performed on
selected genes to verify the gene-array data, including also
some genes that were less than twofold up-regulated but of
potential interest. The quantitative RT-PCR analysis showed
signiWcant up-regulation on day 5 versus day 1 of IFN-,
granzyme A and B, chemokine (C-X-C motif) receptor 3
(CXCR3), and HMMR (Fig. 4). In addition, analysis of gran-
zyme B expression in CD56+ cells, primarily consisting of NK
cells, NKT cells and a subset of CD8+ T cells, showed up-reg-
ulation of granzyme B in this subset as well.
NK cytotoxicity
To examine whether IL-21 therapy increased the cytolytic
activity of circulating NK cells we isolated PBMC in some
patients from the Australian trial at two time points prior to
IL-21 administration and on trial day 5 and used the PBMC
as eVectors against K562 target erythroleukemia cells.
K562 cells are MHC class I deWcient and classical targets
of NK cell-mediated cytotoxicity. An increase in target cell
killing was observed in post-dosing samples compared to
pre-dosing samples in Wve out of six evaluable patients
(Fig. 5). This increase is likely to be underestimated on a
per-NK cell basis as the fraction of circulating NK cells
was signiWcantly lower on day 5 compared to the pre-dose
sample on day 1 (data not shown).Cancer Immunol Immunother (2008) 57:1439–1449 1445
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Discussion
We have demonstrated that IL-21 has detectable and rele-
vant biological eVects on various lymphocyte subsets even
at the lowest dose level tested. We found that within the
dose range tested (1–100 g/kg) IL-21 was able to induce
maximal STAT3 phosphorylation in T cells from the blood
at all dose levels. As previously shown IL-21 therapy
resulted in systemically measurable biological eVects at the
lowest dose level, measured as increased serum sCD25
level and granzyme B expression in CD8+ T cells on study
day 5 [9]. Increases in sCD25 and decreases in circulating
Fig. 3 a Gene ontology (GO-) tree of signiWcantly overrepresented
GO-terms (Biological Process “BP” terms). Each circle in the tree cor-
responds to a particular GO term, and the size of the circle indicates the
degree of overrepresentation (see also ESM Table 2). Circles close to
the root of the tree corresponds to very generic terms whereas circles
closer to the end of the branches represent increasingly speciWc terms.
The ten most signiWcantly overrepresented GO terms are: 1 cell cycle,
2 mitotic cell cycle, 3 cell division, 4 M phase, 5 mitosis, 6 M phase of
mitotic cell cycle, 7 DNA replication, 8 DNA metabolism, 9 spindle
organization and biogenesis, 10 microtubule-based process. b Heat-
map of clustered gene regulations (immunorelated genes). Log2-fold
regulations (day 5 versus day 1 (pre-dose)) for individual patients en-
rolled in the “5 + 9” regimen at six diVerent dose levels are shown.
Some genes are represented by two or three individual probesets. Aver-
age fold regulations (dose levels 30, 50, and 100 g/kg) are listed for
the individual probesets
AB
Fig. 4 Quantitative RT-PCR data. a Analysis of granzyme B and per-
forin mRNA levels in CD8+ and CD56+ cells from patients dosed three
times weekly (“3/week”) or Wve consecutive days of dosing followed
by 9 days with no dosing (“5 + 9”). b Analysis of granzyme A (GZ-
MA), interferon- (IFN-), hyaluronan-mediated motility receptor
(HMMR), and CXCR3 mRNA levels in CD8+ cells from patients in the
5 + 9 regimen. Data from day 1 (pre-dose) and day 5 samples are
shown. Part of Fig. 4a has previously been published [9]
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lymphocytes mediated by IL-21 showed a positive correla-
tion between dose and eVect. Furthermore, increases in per-
cent plasma B cells were observed during dosing. This is
consistent with in vitro data showing that IL-21 promotes B
cell proliferation and diVerentiation into plasma cells [12,
15, 21]. In vitro IL-21 only promotes plasma cell diVerenti-
ation in the context of other B cell stimuli such as CD40;
therefore, even a small increase in circulating plasma B
cells may indicate a pronounced eVect of IL-21 on the frac-
tion of B cells that are activated by other stimuli. Interest-
ingly, the gene array analysis showed that expression of the
prototypical plasma B cell marker, CD38 was increased in
CD8+ cells (Fig. 3b). T cell expression of CD38 is conWned
to a subset of mature T cells showing an activated pheno-
type with high ability to secrete cytokines [38]. Thus, IL-
21-mediated up-regulation of CD38 on CD8+ cells may be
suggestive of T cell activation.
Dosing with IL-21 had signiWcant eVects on a number of
circulating leukocyte subsets. In all lymphocyte subsets,
including B cells, NK cells, and T cells, the number of
circulating cells decreased markedly during dosing, but
returned to pre-dose levels or slightly higher 5 days after
the last dose. The most profound decrease was observed in
NK cells. In contrast, the number of monocytes increased
during dosing and also returned to pre-dose levels 5 days
following the last dose. We do not consider it likely that
these decreases in cells are a result of IL-21 induced apop-
tosis as there was a fast recovery. Rather we consider it
likely that IL-21 therapy results in re-distribution of lym-
phocytes, in which the total number of these cell types in
the body do not necessarily change, but dosing induces the
movement of these cells either out of or into circulation. In
support of this notion we found that 8 out of 10 and 14 out
of 14 evaluable subjects in the 5 + 9 regimen had higher
frequency of CD62L- and CCR7-expressing CD8+ T cells,
respectively; these surface receptors mediate vascular adhe-
sion and migration of T cells to lymph nodes [39]. The true
eVect of IL-21 on CD62L and CCR7 may have been under-
estimated since cells with strong up-regulation would most
likely have left the circulation. The gene array and quantita-
tive RT-PCR analysis revealed that the chemokine recep-
tors CCR5, CXCR6 and CXCR3 were up-regulated in
CD8+ cells supporting increased migratory properties of
these cells. CCR5, CXCR3, and CXCR6 all have “inXam-
matory” chemokines as ligands [31, 33] and could therefore
potentially facilitate the recruitment of eVector lympho-
cytes to sites with tissue injury, inXammation, and/or
tumors. Another gene up-regulated by IL-21 treatment was
HMMR (Fig. 4b). High concentrations of hyaluronan (hyal-
uronic acid (HA)) are often found in areas with rapid cell
proliferation as in tumors [16], and HMMR has an estab-
lished role in HA-stimulated chemotaxis of inXammatory
cells in vitro [49].
A highly signiWcant overrepresentation of genes
involved in cell cycle progression was observed in the
GO-term analysis. Up-regulations of CDK2, cyclin A2,
cyclin B1, cyclin B2, cyclin E1, and cyclin E2 clearly sug-
gest that at least a fraction of the analyzed CD8+ cells tra-
verse the G0 (resting stage) to G1 phase (pre-replication
stage) to the S-phase (replication) transition [32]. These
and other regulations indicate a proliferative eVect of IL-
21 on the CD8+ cells. This is consistent with previous
Wndings that IL-21 can augment proliferation of CD8+ T
cells driven by TCR-stimulation or by IL-15 or IL-7 [35,
50]. In vivo IL-15 and IL-7 may be present in suYcient
amount to act synergistically with IL-21 to induce prolif-
eration, or a subset of CD8+ T cells may have undergone
TCR-driven proliferation enhanced by IL-21 while in the
lymphoid system and subsequently returned to the circu-
lation.
A number of highly interesting gene regulations were
singled out when speciWcally searching for immune related
genes (Fig. 3b) in the list of diVerentially expressed probe
sets. The increased expression of inducible co-stimulator
(ICOS), C1q binding protein, and CD26 in CD8+ cells has
previously been observed in T cell activation [5, 18, 44].
Adenosine deaminase (ADA) which can associate with
CD26 on the cell surface [20] was also found to be up-regu-
lated following IL-21 dosing (Fig. 3b). When binding to
Fig. 5 Enhanced NK cytotoxicity towards K562. PBMC isolated at
screening, day 1 (pre-dose) and day 5 were frozen immediately and
stored in liquid nitrogen. After thawing the PBMC were incubated for
4 h with 51Cr-labeled K562 erythroleukemia cells. For each subject
PBMC from all time points were tested in the same assay
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CD26, ADA has been reported to function as a co-stimula-
tory molecule in T-cell activation [28]. ICOS was also
reported to be up-regulated in the sanroque mouse, a mouse
with mutation in a RING-type ubiquitin ligase which
showed elevated IL-21 levels and development of lupus-
like disease [46]. ICOS plays an important costimulatory
role on follicular helper T cells, which are a main source of
IL-21 [7]. Thus, it is possible that IL-21 has a function in
the regulation of ICOS expression on both CD4+ and CD8+
T cells. IL-17A mRNA was not found to be diVerentially
expressed in the CD8+ T cells following IL-21 dosing (data
not shown), and was in the present study not examined in T
helper cell subsets.
Our data provide several indications that IL-21 adminis-
tration enhanced immune activation and eVector functions.
As previously reported, granzyme B and perforin mRNAs
were up-regulated in CD8+ cells at day 5 of IL-21 treatment
compared to day 1 [9]. In addition we here show that gran-
zyme B mRNA was also up-regulated in CD56+ cells pri-
marily consisting of NK cells. Moreover, granzyme A,
IFN- and cathepsin-C mRNAs were all up-regulated in
CD8+ cells. Perforin and granzymes are crucial proteins in
the granule exocytosis pathway used by CD8+ and NK cells
to kill target cells [47]. Cathepsin-C is a dipeptidyl pepti-
dase which activates granzyme A and B [29, 43] and we
speculate that increased expression of cathepsin-C may
lead to increased activation of the CD8+ cells. Of all the
regulated genes IFN- was most up-regulated. IFN- has a
broad role in activation of innate and adaptive immune
responses and in the protection against viral infections and
tumors [19]. The up-regulations of AIM2 and GBP1 could
be secondary to the IFN- regulation since these genes are
known to be up-regulated by IFN- [6, 10]. The functional
consequences of IL-21 administration were evidenced by
increased cytotoxicity against K562 cells in PBMC isolated
after IL-21 dosing, an eVect that is likely to be mediated by
NK cells.
In conclusion, our data suggest that IL-21 stimulates the
expansion, motility, and eVector functions of CD8+ T-cells
and NK cells in vivo, which may lead to enhanced anti-tumor
immunity. We hypothesize that homing and migration
of cytotoxic T-lymphocytes as well as other lymphocytes
are aVected by IL-21-mediated regulation of chemokine
receptors. All together our data supports the use of IL-21 in
the treatment of cancer.
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